Exploring the mechanism of Bazi Bushen Capsule in delaying age-related macular degeneration based on network pharmacology and in vitro experimental validation
[Objective]To investigate the mechanism of Bazi Bushen Capsules(BZBS)in delaying age-related macular degeneration(AMD)based on network pharmacology and validate it in vitro.[Methods]Constructing a visualization relationship diagram of"traditional Chinese medicine-disease-key target"of BZBS in the treatment of AMD through network pharmacology;GO analysis and KEGG signaling pathway enrichment analysis were performed on the key targets.The freeze-dried powder of BZBS was used to intervene in ARPE-19 cells for in vitro experiments,and whether it could improve D-gal-induced ARPE-19 cellular senescence was examined by ROS staining,β-galactosidase staining(SA-β-gal),Western blot,the ELISA.And validate the signaling pathway results predicted by network pharmacology.[Results]The network pharmacology screening yielded a total of 293 main active ingredients of BZBS,including quercetin,farnesolone A,stigmasterol,and arachidonic acid;the 58 key targets of BZBS and AMD were predicted.In vitro experiments showed that BZBS could effectively increase the viability of senescent ARPE-19 cells,down-regulate the degree of reactive oxygen species,reduce the senescence-related secretion phenotype,and up regulate the expression of P62,and LC3,key proteins of autophagy signaling pathway(P＜0.05).[Conclusion]BZBS can delay the aging process of AMD,and its mechanism may be related to the regulation of autophagy signaling pathway.
万方数据
维普
